A5033196429- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Nitric Oxide and Endothelin Effects
- RNA Interference and Gene Delivery
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cell Adhesion Molecules Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Signaling Pathways in Disease
- Redox biology and oxidative stress
- Immune Response and Inflammation
- Viral Infectious Diseases and Gene Expression in Insects
- Hematopoietic Stem Cell Transplantation
- Cellular transport and secretion
- Epigenetics and DNA Methylation
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
Hospital Universitario 12 De Octubre
2018-2024
Research Institute Hospital 12 de Octubre
2023-2024
Centro de Investigación Biomédica en Red de Cáncer
2019-2024
Spanish National Cancer Research Centre
2021-2024
San Raffaele University of Rome
2023
Memorial Sloan Kettering Cancer Center
2023
Vita-Salute San Raffaele University
2023
Centro de Biología Molecular Severo Ochoa
2012-2020
Universidad Autónoma de Madrid
2012-2020
Consejo Superior de Investigaciones Científicas
2018
Abstract CAR-T-cell therapy against MM currently shows promising results, but usually with serious toxicities. CAR-NK cells may exert less toxicity when redirected resistant myeloma cells. CARs can be designed through the use of receptors, such as NKG2D, which recognizes a wide range ligands to provide broad target specificity. Here, we test this approach by analyzing antitumor activity activated and expanded NK (NKAE) CD45RA − T from patients that were engineered express an NKG2D-based CAR....
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric receptors (CARs) systemically injected bispecific engagers (TCEs), has shown remarkable clinical activity, several products have received market approval. However, despite promising results, patients eventually become refractory relapse, highlighting need for alternative strategies....
The actin cytoskeleton coordinates the organization of signaling microclusters at immune synapse (IS); however, mechanisms involved remain poorly understood. We show here that nitric oxide (NO) generated by endothelial synthase (eNOS) controls coalescence protein kinase C-θ (PKC-θ) central supramolecular activation cluster (c-SMAC) IS. eNOS translocated with Golgi to IS and partially colocalized F-actin around c-SMAC. This resulted in reduced polymerization centripetal retrograde flow...
Abstract Targeted immunotherapies against B-cell maturation antigen (BCMA) have transformed the treatment landscape of Multiple Myeloma (MM). Fc receptor-like 5 (FCRL5) has emerged as an alternative target. However, resistance frequently emerges within months, posing a significant clinical challenge. Structural alterations and mutations in BCMA only account for minority cases insights into escape remain largely unknown. This study investigates novel (epi)genetic mechanisms through...
Mitochondria are involved in the development and acquisition of a malignant phenotype hematological cancers. Recently, their role pathogenesis multiple myeloma (MM) has been suggested to be therapeutically explored. MYC is master regulator b-cell malignancies such as myeloma, its activation known deregulate mitochondrial function. We investigated impact activity on distinct entities disease tested efficacy inhibitor, tigecycline, overcome MM proliferation. COXII expression, COX activity,...
Background CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores potential value ctDNA monitoring with an innovative signature personalized trackable mutations. Method Eleven patients treated anti-CD19 CAR T-cell were included. One did not respond and was excluded. Genomic profiling performed before starting lymphodepleting chemotherapy identify...
Background: Chimeric antigen receptors (CARs) have been used in the past several years cancer therapy to redirect immune effector cells. Despite impressive preliminary efficacy of CAR‐T cells multiple myeloma (MM), NK cell engineering has emerged as a competitive and safer approach. NK‐92 is universal, cheap fast “off‐the‐shelf” cellular therapeutic previously clinical trials. Although modest responses with these reported MM, their oncolytic potential can be enhanced by genetic modification....
Background: HLA-E is highly expressed in several tumor cells, including metastatic and correlates with a poor prognosis. Its interaction the inhibitory receptor NKG2A, T lymphocytes NK enables cell escape. Although α-NKG2A antibodies have not shown positive preclinical clinical results as monotherapy so far, their combination other blocking has promise. Allogeneic CAR-NK cells recently emerged safer immunotherapy than CAR-T but efficacy could be limited due to high NKG2A expression. Aims:...
Abstract DNA promoter methylation acts as a key regulator for gene expression and is deeply altered in tumorigenesis. In the context of tumor clearance, cytotoxic cells (i.e. T NK cells) play critical role. Their function mainly controlled by immune checkpoint (IC) synapse events, where known inhibitory markers are detrimental activation. TIGIT, an receptor on cells, interacts with PVR malignant precluding recognition clearance. Multiple Myeloma (MM) remains incurable disease represents 10%...
Introduction: CAR-T therapy has produced a paradigm shift for the treatment of non-Hodgkin B-cell lymphomas (NHBcL). Strategies to optimize disease surveillance after this are increasingly necessary. This study aims explore potential value circulating tumor DNA (ctDNA) monitoring with an innovative signature personalized trackable mutations. Methods: Twenty-five NHBcL treated CD19 cell were included in 2 academic hospitals (10 follicular lymphoma-FL and 15 large B-cell-LBCL). Clinical...